Infliximab (Remicade, Inflectra, Renflexis)

Infliximab (Remicade, Inflectra, Renflexis) is covered for listed FDA‑approved indications (adult/pediatric Crohn’s and ulcerative colitis ≥6 years, fistulizing Crohn’s, RA, psoriatic arthritis, ankylosing spondylitis, chronic severe plaque psoriasis) and compendial off‑label use for granulomatosis with polyangiitis, but is excluded with active infection and cannot be used concomitantly with other biologics and has a CHF dosing cap (≤5 mg/kg for NYHA III/IV). Authorizations (up to 12 months) require latent TB screening/treatment if positive, specific prior‑therapy failures or contraindications per indication, documentation of improvement for renewals, weight‑based dosing, IV infusion over ≥2 hours, and other condition‑specific documentation.

"Infliximab will not be used in combination with another biologic agent (e."

Sign up to see full coverage criteria, indications, and limitations.